biology-news-1/penn-wistar-team-gains-insight-into-hiv-vaccine-failure-9292-1/;msg18067;topicseen

Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2 AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3 AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4 AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5 AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6 Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2 Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3 Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4 WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2 Alberta companies delivering new products to the health & medical marketplace 2

[0] AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology [0] Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A [0] WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening [0] Alberta companies delivering new products to the health & medical marketplace

Breaking Medicine Technology:Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference 2 Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference 3 Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference 4 ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 2 ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 3 ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 4 ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 5 ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 6 ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 7 FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 2 FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging 3 Chiropractic Marketing Online Coach Launches First of a Kind Wealth Club for Chiropractors 59719 1 Chiropractic Marketing Online Coach Launches First of a Kind Wealth Club for Chiropractors 59719 2 Athens Consulting Volunteers Time To Habitat For Humanity 59714 1 Athens Consulting Volunteers Time To Habitat For Humanity 59714 2 Migraine sufferers more prone to hangover headache 59709 1 Migraine sufferers more prone to hangover headache 59709 2

[0] Ambit Biosciences Corporation Presents Phase I Clinical Results of AC220 in Patients With Acute Myeloid Leukemia at ASH Conference [0] ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease [0] FDA Makes Interim Recommendations to Address Concern of Excess Radiation Exposure during CT Perfusion Imaging